Voriconazole-induced periostitis: beyond post-transplant patients

Joshua D. Reber, Gavin A. McKenzie, Stephen M. Broski

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Voriconazole-induced periostitis (VIP) is a rare but increasingly encountered entity since Food and Drug Administration (FDA) approval of the second generation antifungal medication in 2002. Literature reports most commonly include transplant recipients on immunosuppressive therapy simultaneously requiring antifungal therapy. Nontransplant patients receiving long-term voriconazole have an equal risk of developing the disease, but may experience a delay in diagnosis due to a lack of familiarity with the process outside of the post-transplant and/or immunosuppressed population. We present a case of VIP in a nontransplant, immunocompetent patient on suppressive antifungal therapy for prior abdominal aortic stent graft fungal infection. Radiologist review of current medications and recognition of periostitis on multiple imaging modalities may hasten the diagnosis and lead to earlier treatment and resolution of symptoms.

Original languageEnglish (US)
Pages (from-to)839-842
Number of pages4
JournalSkeletal Radiology
Issue number6
StatePublished - Jun 1 2016


  • Fluoride
  • Fluorosis
  • Medication
  • Metabolic
  • Periostitis
  • Voriconazole

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Voriconazole-induced periostitis: beyond post-transplant patients'. Together they form a unique fingerprint.

Cite this